Feasibility of and patients’ perspective on nilotinib dried blood spot self-sampling
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
PURPOSE: To obtain insight into the feasibility of, and the patients' perspective on, dried blood spot (DBS) self-sampling by patients with chronic myeloid leukemia (CML) using nilotinib. METHODS: Sixty-eight patients with CML using nilotinib participated in this multicenter observational study. Patients were asked to perform blood sampling by means of the DBS method at home just before drug intake (trough level) and to complete a questionnaire including demographics and five questions on their experience with DBS self-sampling. RESULTS: Sixty-one patients (57.5 ± 15.0 years, 49% female) provided 178 DBS samples of which 137 (77%) proved useful in clinical practice. Twenty percent of the samples were rejected because the spot size was too small for analysis. A further 3% were taken at the wrong time. Unsuitable DBS samples were provided by 23 patients. Their educational level was significantly lower than that of patients whose samples were all suitable (p = 0.041). Patients considered DBS self-sampling easy and not painful, and three quarters of the patients performed DBS sampling without additional assistance. Patients' belief in the reliability of DBS self-sampling was moderate to high. It was preferred over venous sampling by 37% of the patients, whereas 39% had no preference. CONCLUSION: DBS self-sampling by CML patients is feasible in clinical practice provided that patients, particularly those with a lower educational level, are adequately instructed about sample collection with emphasis on timing and volume of sample collection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In feasibility studies of DBS self-collection in cancer patients, 90–95% of participants returned DBS samples, and 76–89% reported either preferring DBS or having no preference compared to venipuncture [30, 31].”
From Living Well: Protocol for a web-based program to improve quality of life in rural and urban ovarian cancer survivors (2024) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Picard, S., Titier, K., Etienne, G., Teilhet, E., Ducint, D., Bernard, M.-A., Lassalle, R., Marit, G., Reiffers, J., Begaud, B., et al. (2007) · Blood · doi:10.1182/blood-2006-07-036012 · Cited by 612
Eichhorst, B., Robak, T., Montserrat, E., Ghia, P., Hillmen, P., Hallek, M., & Buske, C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv303 · Cited by 612
Dried Blood Spot Methods in Therapeutic Drug Monitoring: Methods, Assays, and Pitfalls
Edelbroek, P. M., Heijden, J. V. D., & Stolk, L. M. L. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31819e91ce · Cited by 512
Eichhorst, B., Hallek, M., & Dreyling, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq180 · Cited by 456
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Jabbour, E., & Kantarjian, H. (2018) · American Journal of Hematology · doi:10.1002/ajh.25011 · Cited by 413
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hochhaus, A., Saussele, S., Rosti, G., Mahon, F.-X., Janssen, J. J. W. M., Hjorth-Hansen, H., Richter, J., & Buske, C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx219 · Cited by 343
Self-citationTherapeutic Drug Monitoring by Dried Blood Spot: Progress to Date and Future Directions
Wilhelm, A. J., den Burger, J. C. G., & Swart, E. L. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0177-7 · Cited by 342
Self-citationPractical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
Verheijen, R. B., Yu, H., Schellens, J. H. M., Beijnen, J. H., Steeghs, N., & Huitema, A. D. R. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.787 · Cited by 278
Miura, M. (2015) · Biological & Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00103 · Cited by 152
Guilhot, F., Hughes, T. P., Cortes, J. E., Druker, B. J., Baccarani, M., Gathmann, I., Hayes, M., Granvil, C. P., & Wang, Y. L. (2012) · Haematologica · doi:10.3324/haematol.2011.045666 · Cited by 134
Larson, R. A., Yin, O. Q. P., Hochhaus, A., Saglio, G. N., Clark, R. E., Nakamae, H., Gallagher, N. J., Demirhan, E., Hughes, T. P., Kantarjian, H. M., et al. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1200-7 · Cited by 108
Giles, F. J., Yin, O. Q. P., Sallas, W. M., le Coutre, P. D., Woodman, R. C., Ottmann, O. G., Baccarani, M., & Kantarjian, H. M. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1385-4 · Cited by 83
Cheung, C. Y., van der Heijden, J., Hoogtanders, K., Christiaans, M. H. L., Liu, A. Y. L., Chan, Y.-H., Choi, K. S., van de Plas, A., Shek, C. C., Chau, K., et al. (2007) · Transplant International · doi:10.1111/j.1432-2277.2007.00584.x · Cited by 79
Kralj, E., Trontelj, J., Paji, T., & Kristl, A. (2012) · Journal of Chromatography B · doi:10.1016/j.jchromb.2012.07.011 · Cited by 72
Potential of Dried Blood Self-Sampling for Cyclosporine C2 Monitoring in Transplant Outpatients
Leichtle, A. B., Ceglarek, U., Witzigmann, H., Gäbel, G., Thiery, J., & Fiedler, M. (2010) · Journal of Transplantation · doi:10.1155/2010/201918 · Cited by 43
Antunes, M. V., Raymundo, S., Wagner, S. C., Mattevi, V. S., Vieira, N., Leite, R., Reginato, F., Capra, M., Fogliatto, L., & Linden, R. (2015) · Bioanalysis · doi:10.4155/bio.15.101 · Cited by 43
Boons, C. C. L. M., Chahbouni, A., Schimmel, A. M., Wilhelm, A. J., den Hartog, Y. M., Janssen, J. J. W. M., Hendrikse, N. H., Hugtenburg, J. G., & Swart, E. L. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12757 · Cited by 40
Self-citationKromdijk, W., Mulder, J. W., Smit, P. M., ter Heine, R., Beijnen, J. H., & Huitema, A. D. R. (2013) · Antiviral Therapy · doi:10.3851/imp2501 · Cited by 38
Nijenhuis, C. M., Huitema, A. D. R., Marchetti, S., Blank, C. U., Haanen, J. B. A. G., van Thienen, J. V., Rosing, H., Schellens, J. H. M., & Beijnen, J. H. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.728 · Cited by 37
Dried blood spot analysis for therapeutic drug monitoring of pazopanib
de Wit, D., den Hartigh, J., Gelderblom, H. A. J., Qian, Y., den Hollander, M., Verheul, H. M. W., Guchelaar, H., & van Erp, N. P. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.558 · Cited by 33
Willemsen, A. E. C. A. B., Knapen, L. M., de Beer, Y. M., Brüggemann, R. J. M., Croes, S., van Herpen, C. M. L., & van Erp, N. P. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2394-0 · Cited by 26
Jager, N. G. L., Rosing, H., Linn, S. C., Schellens, J. H. M., & Beijnen, J. H. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000224 · Cited by 14
Boons, C. C. L. M., Swart, E. L., Timmers, L., van de Ven, P. M., Janssen, J. J. W. M., & Hugtenburg, J. G. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-247 · Cited by 8
Self-citation
Cited by
Veenhof, H., Koster, R. A., Junier, L. A. T., Berger, S. P., Bakker, S. J. L., & Touw, D. J. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1260 · Cited by 72
Menz, B. D., STOCKER, S. L., Verougstraete, N., Kocic, D., Galettis, P., Stove, C. P., & Reuter, S. E. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14372 · Cited by 55
Zava, T., & Zava, D. T. (2020) · Bioanalysis · doi:10.4155/bio-2020-0289 · Cited by 47
Veenhof, H., van Boven, J. F. M., van der Voort, A., Berger, S. P., Bakker, S. J. L., & Touw, D. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14249 · Cited by 37
Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
Verougstraete, N., Stove, V. V., Verstraete, A., & Stove, C. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.821807 · Cited by 36
Metadata
- Authors
- Boons, C. C. L. M., Timmers, L., Janssen, J. J. W. M., Swart, E. L., Hugtenburg, J. G., & Hendrikse, N. H.
- Affiliations
- Amsterdam Public Health (NL)
- Amsterdam University Medical Centers (NL)
- Corresponding author
- Boons, Christel C. L. M.
- ORCID
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2019-02-07
- Volume
- 75
- Issue
- 6
- Pages
- 825-829
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2911850529
- Cited by
- 36
- References
- 23
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 8 · 2023: 5 · 2022: 6 · 2021: 3 · 2020: 7
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- European Journal of Clinical Pharmacology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Novartis (CAMN107ENL04T)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Keywords
- dried blood spots, self-sampling, nilotinib, chronic myeloid leukemia, trough concentration, patient perspectives, sample rejection, educational attainment, venous blood sampling
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Attitude to Health, Female, Humans, Male, Middle Aged, Patient Participation, Pyrimidines, Self Administration, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Drug Monitoring, Dried Blood Spot Testing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.